

*FORM PTO-1390 OPTIONAL (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371		ATTORNEY'S DOCKET NUMBER 342312003500	
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/868279	
INTERNATIONAL APPLICATION NO. PCT/US99/2927	INTERNATIONAL FILING DATE December 15, 1999	PRIORITY DATE CLAIMED December 16, 1998	
TITLE OF INVENTION CYCLOC PEPTIDE ANTIFUNGAL AGENTS HAVING A SUGAR SUBSTITUENT			
APPLICANT(S) FOR DO/EO/US John Michael RODRIGUEZ, Michael John NESLER, & Mark James ZWEIFEL			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unexecuted) (3 pages).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
<p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment (4 pages).</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Return Receipt Postcard.</p>			
CERTIFICATE OF MAILING BY "EXPRESS MAIL"			
Express Mail Label No.: EL569252183US		Date of Deposit: June 15, 2001	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
 Tamar Yerengas			

U.S. APPLICATION NO. (If known) 09/868279		INTERNATIONAL APPLICATION NO. PCT/US99/29927	ATTORNEY'S DOCKET NUMBER: 342312003500																									
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1,000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provision of PCT Article 33(1)-(4).....\$690.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00</p>																												
ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00																												
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> <th>\$860</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>23 - 20 =</td> <td>3</td> <td>x \$18.00</td> <td>\$54</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td>0</td> <td>x \$80.00</td> <td>\$0</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$270.00</td> </tr> <tr> <td colspan="4"></td> <td>N/A</td> </tr> </tbody> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$860	Total claims	23 - 20 =	3	x \$18.00	\$54	Independent claims	3 - 3 =	0	x \$80.00	\$0	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00					N/A
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$860																								
Total claims	23 - 20 =	3	x \$18.00	\$54																								
Independent claims	3 - 3 =	0	x \$80.00	\$0																								
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00																								
				N/A																								
TOTAL OF ABOVE CALCULATIONS = \$914																												
<p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by $\frac{1}{2}$.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2">SUBTOTAL = \$914</th> </tr> </thead> <tbody> <tr> <td>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>+ \$</td> </tr> <tr> <td colspan="2">TOTAL NATIONAL FEE = \$914</td> </tr> <tr> <td>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</td> <td>+ \$</td> </tr> <tr> <td colspan="2">TOTAL FEES ENCLOSED = \$</td> </tr> <tr> <td><input type="checkbox"/> TU</td> <td>Amount to be refunded:</td> </tr> <tr> <td></td> <td>charged: \$</td> </tr> </tbody> </table>				SUBTOTAL = \$914		Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	+ \$	TOTAL NATIONAL FEE = \$914		Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property	+ \$	TOTAL FEES ENCLOSED = \$		<input type="checkbox"/> TU	Amount to be refunded:		charged: \$											
SUBTOTAL = \$914																												
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	+ \$																											
TOTAL NATIONAL FEE = \$914																												
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property	+ \$																											
TOTAL FEES ENCLOSED = \$																												
<input type="checkbox"/> TU	Amount to be refunded:																											
	charged: \$																											
<p>a. <input type="checkbox"/> A check in the amount of \$ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 03-1952 in the amount of \$914.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Deposit Account No. 03-1952. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>																												
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>																												
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Madeline I. Johnston Morrison & Foerster LLP 755 Page Mill Road Palo Alto, California 94304-1018</p>																												
 <small>SIGNATURE</small> <p>Madeline I. Johnston Registration No. 36,174</p>																												

09/868279

PATENT

Docket No. 342312003500

JC03 Rec'd PCT/PTC 15 JUN 2001

15 JUN 2001

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL5692521830US

Date of Deposit: June 15, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Tamara Venegas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

John M. RODRIGUEZ et al.

Serial No.: To Be Assigned

Int'l. Application No.: PCT/US99/29927

Int'l. Filing Date: December 15, 1999

For: CYCLIC PEPTIDE ANTIFUNGAL
AGENTS HAVING A SUGAR
SUBSTITUENT

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

PRELIMINARY AMENDMENT

BOX PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The above-referenced application is being filed herewith under 35 U.S.C. §371.

Please enter the following amendments in the above referenced application.

AMENDMENTS

In the Specification

On page 1, after the Title, please insert:

CROSS REFERENCE TO RELATED APPLICATIONS

This is a U.S. National Phase of International Application PCT/US99/29927, filed on December 15, 1999, which claims priority to U.S. Provisional Patent Application Serial No. 60/112,433, filed on December 16, 1998, the disclosures of which are incorporated herein by reference in their entirety.

REMARKS

The specification has been amended to include the priority information. The attached page is captioned "Version With Markings to Show Changes Made".

0985827-6020602


CONCLUSION

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 342312003500. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: June 15, 2001

By:



Madeline I. Johnston
Registration No. 36,174

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5840
Facsimile: (650) 494-0792

Version With Markings to Show Changes Made

In the Specification

On page 1, after the Title, please insert:

--CROSS REFERENCE TO RELATED APPLICATIONS

This is a U.S. National Phase of International Application PCT/US99/29927, filed on December 15, 1999, which claims priority to U.S. Provisional Patent Application Serial No. 60/112,433, filed on December 16, 1998, the disclosures of which are incorporated herein by reference in their entirety--.

09632679.020602

CYCLIC PEPTIDE ANTFUNGAL AGENTS HAVING A SUGAR SUBSTITUENTTECHNICAL FIELD

5 The invention relates to anti-fungal/anti-parasitic agents, in particular, derivatives of Echinocandin compounds and their use in treatment of fungal and parasitic infections.


BACKGROUND ART

10 A number of naturally occurring cyclic peptides are known in the art including Echinocandin B (A30912A), Aculeacin, Mulundocandin, Sporofungin, L-671,329, and S31794/F1. In general, these cyclic peptides can be structurally characterized as a cyclic hexapeptide core (or nucleus) with an acylated amino group on one of the core amino acids. This acyl group is typically a fatty acid moiety forming a side chain off the nucleus. For example, Echinocandin B has a linoleoyl side chain while Aculeacin has a palmitoyl side chain.


15 These natural products have limited inherent antifungal and antiparasitic properties. The natural compounds can be structurally modified to enhance these properties or improve the compound's stability and/or water solubility. Turner et al., *Cur. Pharm. Des.* 2:209 (1996). For example, the fatty acid side chain can be removed from the cyclic peptide core to provide an amino nucleus which can then be re-acylated to provide semi-synthetic compounds.

DISCLOSURE OF THE INVENTION



20 A compound represented by the following structure I is provided.



where R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; R¹ is independently -H, -OH or -O-Pg; R² is -H, -CH₃, -NH₂, or -NH-Pg; R³ is -H, -CH₃, -CH₂CONH₂, -CH₂CONH-Pg, -CH₂CH₂NH₂, or -CH₂CH₂NH-Pg; R⁴ is -H, -OH, or -O-Pg; R⁵ is -OH, -OSO₃H, or -OPO₂HR^a, where R^a is hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzyloxy, *p*-halobenzyl, *p*-halobenzyl, *p*-nitrobenzyl, or *p*-nitrobenzyl; R⁶ is -H, -OH, or -OSO₃H; R⁷ is -H or -CH₃; t is an integer from 2-7; R⁸ is a sugar moiety of the formula



where R⁹ is independently -H, -OH, -N₃, -O-Pg, -NH₂, -NH-Pg, or a second sugar moiety comprising one to three sugar units selected from the group consisting of



thereof, where R^{9a} is -H, -OH, -N₃, -NH₂, -O-Pg, or -NH-Pg, R^{9b} is -OPO₂R^a, -OSO₃H, -H, -NH₂, -OH, -O-Pg, or -NH-Pg, R^{9c} is -CH₃, -CH₂OH, -CH₂N₃, -CH₂OSO₃H, -CH₂NH-Pg, -CH₂O-Pg, -CO₂H, or -CO₂-Pg, where R^a is as defined above, and so long as no more than one R⁹ is represented by said second sugar moiety; Pg is a protecting group (i.e., -O-Pg is a hydroxy protecting group, -NH-Pg is an amino protecting group, -CH₂CONH-Pg is an amido protecting group and -CO₂-Pg

is a carboxy protecting group); and pharmaceutically acceptable salts, esters, hydrates or solvates thereof.

The invention encompasses a pharmaceutical formulation of one or more pharmaceutical carriers, diluents or excipients and a compound represented by structure I described above.

The invention further encompasses a method of inhibiting fungal and parasitic activity by administering an effective amount of a compound represented by structure I to a recipient in need of thereof.

"Alkyl" refers to a hydrocarbon radical of the general formula C_nH_{2n+1} containing from 1 to 30 carbon atoms unless otherwise indicated. The alkane radical can be straight, branched, cyclic, or multi-cyclic. The alkane radical can be substituted or unsubstituted. Similarly, the alkyl portion of an alkoxy group, alkylthio group or alkanoate have the same definition as above.

"C₁-C₁₂ alkyl" refers to a straight or branched saturated alkyl chain having from one to twelve carbon atoms. C₁-C₁₂ alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, 5-methylpentyl, hexyl, heptyl, 3,3-dimethylheptyl, octyl, 2-methyl-octyl, nonyl, decyl, undecyl and dodecyl. "C₁-C₁₂ alkyl" includes "C₁-C₆ alkyl", "C₁-C₄ alkyl", and "C₃-C₁₂ cycloalkyl."

"C₃-C₁₂ cycloalkyl" refers to a cyclic saturated alkyl chain having from 3 to 12 carbon atoms. Moreover, "C₃-C₁₂ cycloalkyl" includes "C₃-C₇ cycloalkyl", i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

"C₁-C₁₂ alkoxy" refers to a C₁-C₁₂ alkyl group attached through an oxygen atom. C₁-C₁₂ alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, sec-butoxy, n-pentoxy, 5-methyl-hexaoxy, heptoxy, octyloxy, decyloxy and dodecyloxy. "C₁-C₁₂ alkoxy" includes "C₁-C₆ alkoxy", "C₃-C₇ alkoxy", and "C₁-C₄ alkoxy".

"C₁-C₁₂ alkylthio" refers to a C₁-C₁₂ alkyl group attached through a sulfur atom. C₁-C₁₂ alkylthio groups include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, butylthio, 3-methyl-heptylthio, octylthio, and 5,5-dimethylhexylthio. "C₁-C₁₂ alkylthio" includes "C₁-C₆ alkylthio" and "C₁-C₄ alkylthio."

“Alkenyl” refers to an acyclic hydrocarbon containing at least one carbon-carbon double bond. The alkene radical can be straight, branched, cyclic, or multi-cyclic. The alkene radical can be substituted or unsubstituted.

5 “Alkynyl” refers to an acyclic hydrocarbon containing at least one carbon-carbon triple bond. The alkyne radical can be straight, or branched. The alkyne radical can be substituted or unsubstituted.

10 “C₂-C₁₂ alkynyl” refers to a straight or branched mono-alkynyl chain having from two to twelve carbon atoms. C₂-C₁₂ alkynyl groups include, but are not limited to, ethynyl, 1-propyn-1-yl, 1-propyn-2-yl, 1-butyn-1-yl, 1-butyn-3-yl, 1-pentyn-3-yl, 4-pentyn-2-yl, 1-hexyn-3-yl, 3-hexyn-1-yl, 5-methyl-3-hexyn-1-yl, 5-octyn-1-yl, 7-octyn-1-yl, 4-decyn-1-yl and 6-decyn-1-yl.

15 “Aryl” refers to aromatic moieties having single (e.g., phenyl) or fused ring systems (e.g., naphthalene, anthracene, phenanthrene, etc.). The aryl groups can be substituted or unsubstituted. Substituted aryl groups include a chain of aromatic moieties (e.g., biphenyl, terphenyl, phenylnaphthalyl, etc.).

20 “Heteroaryl” refers to aromatic moieties containing at least one heteroatom within the aromatic ring system (e.g., pyrrole, pyridine, indole, thiophene, furan, benzofuran, imidazole, pyrimidine, purine, benzimidazole, quinoline, etc.). The aromatic moiety can be a single or fused ring system. The heteroaryl groups can be substituted or unsubstituted.

25 Within the field of organic chemistry and particularly within the field of organic biochemistry, it is widely understood that significant substitution of compounds is tolerated or even useful. In the present invention, for example, the term alkyl group allows for substituents which are a classic alkyl, such as methyl, ethyl, propyl, *n*-butyl, *t*-butyl, *t*-butyl, hexyl, isoctyl, dodecyl, stearyl, etc. The term group specifically envisions and allows for substitutions on alkyls which are common in the art, such as hydroxy, halogen, alkoxy, carbonyl, keto, ester, carbamato, etc., as well as including the unsubstituted alkyl moiety. However, it is generally understood by those skilled in the art that the substituents should be selected so as to not adversely affect the pharmacological characteristics of the compound or adversely interfere with the use of the medicament. The same is true for each of the other groups (i.e., aryl, alkynyl, alkenyl, heteroaryl). Suitable substituents for any of the groups defined above include alkyl, alkenyl, alkynyl, aryl, halo, hydroxy, alkoxy, aryloxy, mercapto,

03882279.020600

alkylthio, arylthio, mono- and di-alkyl amino, quaternary ammonium salts, aminoalkoxy, hydroxyalkylamino, aminoalkylthio, carbamyl, carbonyl, carboxy, glycolyl, glycyl, hydrazino, guanyl, and combinations thereof.

"Halo" refers to chloro, fluoro, bromo and iodo.

5 "O-Pg" and "hydroxy protecting group" refer to a substituent of a hydroxy group that is commonly employed to block or protect the hydroxy functionality while reactions are carried out on other functional groups on the compound. This substituent, when taken with the oxygen to which it is attached, can form an ether, e.g., methyl, methoxymethyl, and benzyloxymethyl ether, a silyl ether, an ester, e.g. 10 acetoxy, or a sulfonate moiety, e.g. methane and p-toluenesulfonate. The exact genus and species of hydroxy protecting group is not critical so long as the derivatized hydroxy group is stable to the conditions of subsequent reaction(s) and the protecting group can be removed at the appropriate point without disrupting the remainder of the molecule. A preferred hydroxy protecting group is acetyl. Specific examples of 15 hydroxy protecting groups are described in Greene, "Protective Groups in Organic Synthesis," John Wiley and Sons, New York, N.Y., (2nd ed., 1991), ("Greene") chapters 2 and 3 and in the Preparations and Examples sections which follow.

20 "NH_p-Pg" and "amino protecting group" refer to a substituent of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups on the compound. When p is 0, the amino protecting group, when taken with the nitrogen to which it is attached, forms a cyclic imide, e.g., phthalimido and tetrachlorophthalimido. When p is 1, the protecting group, when taken with the nitrogen to which it is attached, can form a carbamate, e.g., methyl, ethyl, and 9-fluorenylmethylcarbamate; or an amide, e.g., N-formyl and N- 25 acetyl amide. The exact genus and species of amino protecting group employed is not critical so long as the derivatized amino group is stable to the condition of subsequent reaction(s) on other positions of the intermediate molecule and the protecting group can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amino protecting group(s). Preferred amino 30 protecting groups are *t*-butoxycarbonyl (*t*-Boc), allyloxycarbonyl, phthalimido, and benzyloxycarbonyl (CbZ). Further examples of groups referred to by the above terms are described in *Greene* at chapter 7.

"-CO₂-Pg" and "carboxy protecting group" refer to a substituent of a carbonyl that is commonly employed to block or protect the carboxy functionality while reactions are carried out on other functional groups on the compound. This substituent, when taken with the carbonyl to which it is attached, can form an ester, e.g., C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, benzyl, substituted benzyl, benzhydryl, substituted benzhydryl, triyl, substituted triyl, and trialkylsilyl ester. The exact species of carboxy protecting group is not critical so long as the derivatized carboxy group is stable to the conditions of subsequent reaction(s) and the protecting group can be removed at the appropriate point without disrupting the remainder of the molecule. Other examples of groups referred to by the above terms are described in *Greene*, at chapter 5.

"C(O)NH-Pg" and "amido protecting group" refer to a substituent of an amide commonly employed to block or protect the amino portion while reacting other functional groups on the compound. This protecting group, when taken with the nitrogen to which it is attached, can form an amide, e.g. N-allyl, N-methoxymethyl, and N-benzyloxymethyl amide. The exact species of amido protecting group employed is not critical so long as the derivatized amido group is stable to the condition of subsequent reaction(s) on other positions of the intermediate molecule and the protecting group can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amido protecting group(s). Other examples of groups referred to by the above terms are described in *Greene*, at chapter 7, pg. 397.

"Carbonyl activating group" refers to a substituent of a carbonyl that promotes nucleophilic addition reactions at that carbonyl. Suitable activating substituents are those which have a net electron withdrawing effect on the carbonyl. Such groups include, but are not limited to, alkoxy, aryloxy, nitrogen containing aromatic heterocycles, or amino groups such as oxybenzotriazole, imidazolyl, nitrophenoxy, pentachlorophenoxy, N-oxysuccinimide, N,N'-dicyclohexylsoure-O-yl, N-hydroxy-N-methoxyamino; acetates, formates, sulfonates such as methanesulfonate, ethanesulfonate, benzenesulfonate, or p-tolylsulfonate; and halides such as chloride, bromide, or iodide.

"Pharmaceutical" or "pharmaceutically acceptable" means substantially non-toxic and substantially non-deleterious to the recipient. "Pharmaceutical formulation"

means that the carrier, solvent, excipients and salt are compatible with the active ingredient of the formulation (i.e., Compound I).

5 "Pharmaceutical salt" or "pharmaceutically acceptable salt" refers to salts of the compounds represented by structure I that are substantially non-toxic to the recipient at the doses administered. Typical pharmaceutical salts include those prepared by reaction of the compounds of the invention with a mineral or organic acid or inorganic base. Such salts are known as acid addition and base addition salts. For further exemplification, see e.g. Berge et al., *J. Pharm. Sci.*, 66:1 (1977).

10 "Solvate" is an aggregate that comprises one or more molecules of the solute, such as a formula I compound, with one or more molecules of a pharmaceutical solvent, including, but not limited to, water and ethanol. "Suitable solvent" is any solvent, or mixture thereof, inert to the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction.

15 "Thermodynamic base" is a base that provides a reversible deprotonation of an acidic substrate or is a proton trap for protons produced as reaction byproducts, and is reactive enough to effect the desired reaction without significantly effecting any undesired reactions. Examples of thermodynamic bases include, but are not limited to, acetates, acetate dihydrates, carbonates, bicarbonates, C₁-C₄ alkoxides, and hydroxides (e.g. silver, lithium, sodium, or potassium acetate, acetate dihydrate, carbonate, bicarbonate, methoxide, or hydroxide), tri-(C₁-C₄ alkyl)amines, or aromatic nitrogen containing heterocycles (e.g. imidazole and pyridine).

20 "Inhibiting" includes prohibiting, stopping, retarding, alleviating, ameliorating, halting, restraining, slowing or reversing the progression, or reducing the severity of the growth or any attending characteristics, symptoms, and results from the existence of a parasite or fungus. These methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate.

25 "Effective amount" refers to an amount of a compound of formula I which is capable of inhibiting fungal and/or parasitic activity.

30 "Recipient" includes mammals, preferably, humans.

BEST MODE FOR CARRYING OUT THE INVENTION


Compounds represented by structure I have now been found to be useful as antifungal and antiparasitic agents or as an intermediate thereof. The most convenient

20020167289860

means of producing compounds represented by structure I is by modifying naturally occurring compounds.

For illustrative purposes, Scheme I (below) starts with a specific Echinocandin derivative. However, one could begin with any natural product, semi-synthetic or synthetic Echinocandin-type compound containing a hemiaminal group.

The term "Echinocandin-type compounds" refers to compounds having the following general structure including any simple derivatives thereof:




wherein R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or heteroaryl group; R¹ is -H or -OH; R² is -H, -NH₂ or -CH₃; R³ is -H, -CH₃, -CH₂CONH₂ or -CH₂CH₂NH₂; R⁴ is -H or -OH; R⁵ is -OH, -OSO₃H, or -OPO₂HR^a, where R^a is hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, phenyl, phenoxy, p-halophenyl, p-halophenoxy, p-nitrophenyl, p-nitrophenoxy, benzyl, benzyloxy, p-halobenzyl, p-halobenzylxy, p-nitrobenzyl, or p-nitrobenzylxy; R⁶ is -H, -OH, or -OSO₃H; R⁷ is -H or -CH₃; and pharmaceutically acceptable salts, esters, hydrates or solvates thereof.

"Natural product" is those secondary metabolites, usually of relatively complex structure, which are of more restricted distribution and more characteristic of a specific source in nature. Suitable natural product starting materials of the Echinocandin cyclopeptide family include Echinocandin B, Echinocandin C, Aculeacin A_γ, Mulundocandin, Sporofungin A, Pneumocandin A₀, WF11899A, and Pneumocandin B₀.

The cyclic peptides used in the invention can be produced by culturing various microorganisms. In general, the cyclic peptides can be characterized as a cyclic hexapeptide nucleus with an acylated amino group on one of the amino acids. The

amino group on the naturally-occurring cyclic peptide is typically acylated with a fatty acid group forming a side chain off the nucleus. Examples of naturally-occurring acyl groups include, but are not limited to, linoleoyl (Echinocandin B, C and D), palmitoyl (Aculeacin A_Y and WF11899A), stearoyl, 12-methylmyristoyl (Mulundocandin), 10,12-dimethylmyristoyl (Sporiofungin A and Pneumocandin A₀).


Semi-synthetic derivatives can be generally prepared by removing the fatty acid side chain from the cyclic peptide nucleus to produce a free amino group (i.e., no pendant acyl group -C(O)R). The free amine is then re-acylated with a suitable acyl group. For example, the echinocandin B nucleus has been re-acylated with certain nonnaturally occurring side chain moieties to provide a number of antifungal agents. U.S. Patent No. 4,293,489. The N-acyl side chain encompasses a variety of side chain moieties known in the art. Suitable side chain moieties include substituted and unsubstituted alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups and combinations thereof. Preferably, the side chain contains both a linearly rigid section and a flexible alkyl section to maximize antifungal potency. Representative examples of preferred acyl side chains include R groups having the following structures:



where A, B, C and D are independently hydrogen, C₁-C₁₂ alkyl, C₂-C₁₂ alkynyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkylthio, halo, or -O-(CH₂)_m-[O-(CH₂)_n]_p-O-(C₁-C₁₂ alkyl) or -O-(CH₂)_q-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and E is hydrogen, C₁-C₁₂ alkyl, C₃-C₁₂ cycloalkyl, benzyl or C₃-C₁₂ cycloalkylmethyl.

Scheme I illustrates the general semi-synthetic route described above where a natural product (Compound II(a)) is modified to provide an intermediate (Compound

II(d)) which is then further modified to provide a representative example of Compound I as illustrated in Scheme II.



Scheme I

Cyclic peptides represented by structure II(a) can be prepared by fermentation of known microorganisms. For example, the cyclic peptide II(a) where R^1 and R^4 are each hydroxy, R^2 , R^3 and R^7 are each methyl (cyclic nucleus corresponding to A-


30912A) can be prepared using the procedure detailed in U.S. Patent No. 4,293,482. Cyclic peptide II(a) where R¹ is hydroxy, R², R³ and R⁷ are each methyl, and R⁴ is hydrogen (cyclic nucleus corresponding to A-30912B) can be prepared using the procedure detailed in U.S. Patent No. 4,299,763. Aculeacin can be prepared using the procedure detailed in U.S. Patent No. 3,978,210. Cyclic peptide II(a) where R³ is CH₂C(O)NH₂, R⁷ is methyl, R² is hydrogen, and R¹ and R⁴ are hydroxy can be prepared using the procedure detailed in U.S. Patent No. 5,198,421.

Cyclic peptide II(a) can be deacylated using procedures known in the art to provide an amino nucleus represented by structure II(b). This reaction is typically carried out enzymatically by exposing the naturally occurring cyclic peptide to a deacylase enzyme. The deacylase enzyme can be obtained from the microorganism *Actinoplanes utahensis* and used substantially as described in U.S. Patent Nos. 4,293,482 and 4,304,716. The deacylase enzyme can also be obtained from the *Pseudomonas* species. Deacylation can be accomplished using whole cells of *A. utahensis* or *Pseudomonas* or the crude or purified enzyme thereof or using an immobilized form of the enzyme. See European Patent Application No. 0 460 882. Examples of naturally occurring cyclic peptides that can be used as starting materials include, but are not limited to, aculeacin (palmitoyl side chain), tetrahydroechinocandin B (stearoyl side chain), mulundocandin (branched C₁₅ side chain), L-671,329 (C₁₆ branched side chain), S 31794/F1 (tetradeccanoyl side chain), sporiofungin (C₁₅ branched side chain), FR901379 (palmitoyl side chain). A preferred cyclic peptide is echinocandin B (Compound II(a) where R¹ and R⁴ are each hydroxy, R², R³ and R⁷ are each methyl, and R^{5a} is linoleoyl).

The amino nucleus II(b) can be re-acylated, by procedures taught in U.S. Patent Nos. 5,646,111, and 5,693,611 to provide compounds represented by structure II(c). See Preparation 12 below for an example of this transformation. Also see, U.S. Patent Nos. 5,646,111 and 5,693,611 for preparation of the acyl groups at R. Cyclic peptides II(c) where R contains 1 or more heterocyclic rings can be prepared as taught in U.S. Patent No. 5,693,611.

Compound II(d) can then be prepared by selective etherification of Compound II(c) as taught in *J. Antibiotics*, 51:239-242 (1998) and U.S. Patent No. 5,652,213.

The compounds represented by structure I can be prepared from compounds of structure II(d) as illustrated in Scheme II below where R^{10} is a carbonyl activating group and t, R, R^1 , R^2 , R^3 , R^4 , R^7 and R^9 are as defined above.




Scheme II

Compound I can be prepared by adding either Compound III or IV to Compound II(a) dissolved or suspended in a suitable solvent in the presence of a suitable thermodynamic base. A convenient and preferred solvent for the reaction is dimethylformamide while a convenient and preferred base is triethylamine. The reaction can be performed at from 0°C to the reflux temperature of the mixture but is typically performed at ambient temperatures for about 24 hours. See Example 1 below for an example of specific reaction conditions.

Compounds represented by structures III and IV are known in the art and if not commercially available can be synthesized by techniques well known in synthetic chemical arts. Collins et al., "Monosaccharides: Their Chemistry and Their Roles in Natural Products," John Wiley and Sons, New York, NY, 1995; and "Methods in Carbohydrate Chemistry", Vol VI, Academic Press, New York, N.Y., 1980.

Compounds III and IV where R^9 is hydroxy are known as carbohydrates or monosaccharides (sugars). These sugars can be modified by replacing one or more hydroxy groups with hydrogen, azide, or amino to provide the other derivatives of Compounds III and IV including disaccharides and polysaccharides where R^9 is a second sugar moiety. Such compounds can be prepared as illustrated in Scheme 3 below where Lg is an activated hydroxy leaving group.



Scheme 3

A commercially available Compound VI can have its hydroxy group(s) activated for nucleophilic displacement by standard techniques known in the art. For example, the hydroxy group can be sulfonylated with methane-, benzene-, or p-toluene-sulfonyl chloride (or bromide) to provide a Compound VII where Lg is OSO_2Me , OSO_2 -phenyl, or OSO_2 -p-toluenyl. At this point, the leaving group can be displaced by azide ion, e.g., from sodium or potassium azide. Alternatively, the leaving group can be displaced by iodide ion from, e.g., sodium or potassium iodide. The resulting Compound VIII can be reduced to form a Compound IX where one or more of R^{9a} or R^{9b} is amino or hydrogen by catalytic hydrogenation or with a reducing agent such as nickel chloride hexahydrate. It is preferred that when an amino group is desired in the final product Compound I, that any azido groups are converted to amino groups after coupling to Compound II(d).


Compound I, where any of R^9 is amino can be formed from a Compound I where R^9 is azido as described by analogous procedures well known in the art. See, e.g., Larock, "Comprehensive Organic Transformations," pg. 409, VCH Publishers, New York, N.Y., 1989.

Compound I where R^5 , R^9 , R^{9a} , R^{9b} , and/or R^{9c} is a hydroxy group, can be phosphorylated or phosphonylated by reaction with an appropriately substituted dichloro- phosphate or phosphonic acid of formula V



5

in the presence of a suitable base to provide, following an aqueous work-up, to produce Compound I where R^5 , R^9 , R^{9a} , R^{9b} , and/or R^{9c} are moieties of the formula



, respectively.

Suitable bases include lithium trimethylsilanolate (LiOTMS), and lithium bis(trimethylsilyl)amide (LHMDS). A preferred solvent is an aprotic solvent such as tetrahydrofuran and/or dimethylformamide. U.S. Patent No. 5,693,611.

Alternatively, the compounds represented by structure I where R^{9b} is hydroxy and/or R^{9c} is hydroxymethyl can be sulfated by reaction with a suitable sulfation reagent. Guiseley et al., *J. Org. Chem.*, 26:1248 (1961). The protected compound of structure I can have its protecting group(s) removed to form a deprotected Compound I. Initial choices of protecting groups, and methods for their removal, are well known in the art. See, e.g., Greene.


Pharmaceutical salts are typically formed by reacting Compound I with an equimolar or excess amount of acid or base. The reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, and the like for acid addition salts, or water, an alcohol or a chlorinated solvent such as methylene chloride for base addition salts. The salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods.

Acids commonly employed to form acid addition salts are inorganic acids including, but not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and organic acids such as *p*-toluenesulfonic, methanesulfonic acid, ethanesulfonic acid, oxalic acid, *p*-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, tartaric acid, benzoic acid, acetic acid.


Base addition salts include those derived from inorganic bases, including, but not limited to, ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates. Bases useful in preparing salts of this invention include, but are not limited to, sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide and calcium carbonate.

The particular counterion forming a part of any salt of this invention is not of a critical nature, provided the salt as a whole is pharmacologically acceptable and the counterion does not contribute undesired qualities to the salt as a whole. Preferred pharmaceutical acid addition salts are those formed with mineral acids such as hydrochloric acid and sulfuric acid, and those formed with organic acids such as maleic acid, tartaric acid, and methanesulfonic acid. Preferred pharmaceutical base addition salts are the potassium and sodium salt forms.


Preferred compounds of the present invention are those compounds represented by structure I where R¹ is hydroxy at each occurrence; R⁴ is hydroxy; R², R³, and R⁷ are each methyl; R is a moiety of the formula




R⁸ is methyl or methoxy; or a pharmaceutically acceptable salt or solvate thereof. More preferable are those compounds wherein R⁵ is hydroxy; R is a moiety of the formula



R⁸ is a moiety of the formula:



D is hydrogen or C₃-C₇ alkoxy; R⁹ is independently hydrogen, hydroxy, amino, or a moiety of the formula:




where R^{9b} is $-OPO_2R^a$, $-OSO_3H$, $-H$, $-NH_2$, $-OH$, $-O-Pg$, or $-NH-Pg$ and n is 1, 2, or 3; or a pharmaceutically acceptable salt or solvate thereof. Even more preferable are those compounds wherein D is n -pentoxy; R^9 is independently hydroxy or amino; or a pharmaceutically acceptable salt or solvate thereof. Most preferred are those compounds wherein R^9 is hydroxy at each occurrence; and t is 2; or a pharmaceutically acceptable salt or solvate thereof.

The optimal time for performing the reactions of Schemes 1 - 3 can be determined by monitoring the progress of the reaction by conventional chromatographic techniques. Choice of reaction solvent is generally not critical so long as the solvent employed is inert to the ongoing reaction and sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction. Unless otherwise indicated, all of the reactions described herein are preferably conducted under an inert atmosphere. A preferred inert atmosphere is nitrogen. Once a reaction is complete, the intermediate compound can be isolated by procedures well-known in the art, for example, the compound can be crystallized or precipitated and then collected by filtration, or the reaction solvent can be removed by extraction, evaporation or decantation. The intermediate compound can be further purified, if desired, by common techniques such as crystallization, precipitation, or chromatography over solid supports such as silica gel, alumina and the like, before carrying out the next step of the reaction scheme.

The following examples are meant to illustrate but not limit the invention. All references cited herein are hereby incorporated herein by reference.


The following Preparations and Examples further describe synthesis of the compounds. "Fast atom bombardment mass spectroscopy" and "high performance liquid chromatography" are abbreviated "MS(FAB)" and "HPLC", respectively.

Preparation 1

5 The A-30912A nucleus (60.2 mmol) and the 2,4,5-trichlorophenol ester of
 [(4"-pentyloxy)-1,1':4',1"-terphenyl]-4-carboxylic acid (26.0 g, 48.2 mmol) were
 combined in 8.5 L of dimethylformamide. The resultant reaction mixture was stirred
 for approximately 48 hours at room temperature (RT) and the solvent was removed *in*
vacuo to provide a residue. This residue was slurried in ether, collected by filtration,
 washed with methylene chloride and dissolved in methanol or a 1:1 (v/v)
 acetonitrile/water mixture. The resultant solution is subjected to reverse phase HPLC
 (C18; eluent of 20-40% aqueous acetonitrile containing 0.5% monobasic ammonium
 phosphate (w/v); 20 mL/min.; 230 nm). After removing the unreacted A30912A
 nucleus, the desired product is eluted from the column using an eluent of aqueous
 acetonitrile. The fractions containing the desired product are combined and then
 concentrated *in vacuo* or lyophilized to provide 18 g of the title compound.

10 15 MS(FAB): 1140.5103 (M^{+1}).


02868275 020602

Preparation 2


The compound of Preparation 1 (1.08 g, 0.9 mmol) and ethanolamine hydrochloride (185 mg, 1.9 mmol) were dissolved in about 20 mL of dimethylsulfoxide. Hydrogen chloride was blown over the solution for about 5 seconds. The resulting mixture was stirred at room temperature under nitrogen for 28 hours. The reaction solution was subjected to reverse-phase HPLC (C18; eluent of 60% acetonitrile in water containing 0.1% trifluoroacetic acid (v/v); 40 mL/min.; 280 nm). The fractions containing the desired product were combined and concentrated *in vacuo* or lyophilized to provide the title compound. MS(FAB):1183.5577 (M+H).
 5
 10

Examples 1 and 2

Examples 1 and 2 have the following base structure:




Example 1



5 α -D-Galacturonic acid (388 mg, 2.0 mmol) and N-hydroxysuccinimide (NHS)
 (230 mg, 2.0 mmol) were dissolved in anhydrous dimethylformamide. The mixture
 was cooled in an ice bath under nitrogen and dicyclohexylcarbodiimide (DCC)
 (412 mg, 2.0 mmol) was added. The ice bath was removed and the resulting mixture
 was stirred overnight and then the reaction solution was filtered directly into a flask
 containing the compound of Preparation 2 (240 mg, 0.2 mmol). Triethylamine
10 (0.030 mL, 0.2 mmol) was then added and the resulting mixture was stirred at room
 temperature under nitrogen for 48 hours. The resultant solution was subjected to
 reverse-phase HPLC (C18; eluent of 60% acetonitrile in water, 280 nm). The
 fractions containing the desired product were combined and then concentrated *in*
 vacuo or lyophilized to provide the title compound. MS(FAB): 1381 ($M^+ + Na$).

Example 2



D-Glucuronic acid (194 mg, 1.0 mmol) and the compound of Preparation 2 were converted to the title compound by the procedure of Example 1.

The compounds represented by structure I have been shown to exhibit a variety of antifungal and antiparasitic activities to various degrees. For example, the compounds of structure I can inhibit the growth of various infectious fungi including *Candida spp.* (e.g., *C. albicans*, *C. parapsilosis*, *C. krusei*, *C. glabrata*, *C. tropicalis*, or *C. lusitanae*), *Torulopsis spp.* (e.g., *T. glabrata*), *Aspergillus spp.* (e.g., *A. fumigatus*), *Histoplasma spp.* (e.g., *H. capsulatum*), *Cryptococcus spp.* (e.g., *C. neoformans*), *Blastomyces spp.* (e.g., *B. dermatitidis*), *Fusarium spp.*, *Trichophyton spp.*, *Pseudallescheria boydii*, *Coccidioides immitis*, *Sporothrix schenckii* and the like.

Antifungal activity of a test compound is determined *in vitro* by obtaining the minimum inhibitory concentration (MIC) of the compound using a standard agar dilution test or a disc-diffusion test. The compound is then tested *in vivo* (in mice) to determine the effective dose for controlling a systemic fungal infection.

5 Accordingly, representative compounds of the present invention were tested for, and displayed, antifungal activity against at least one of the following fungi: *C. albicans*, *C. parapsilosis*, *C. neoformans*, *Histoplasma spp.*, and *A. fumigatus*.

10 The compounds also inhibit growth of certain organisms primarily responsible for opportunistic infections in immunosuppressed individuals. For example, the compounds inhibit the growth of *Pneumocystis carinii* the causative organism of pneumocystis pneumonia (PCP) in AIDS and other immunocompromised recipients. "Topley and Wilson's Microbiology and Microbial Infections," Vol. 5, Ch. 22, Oxford University Press, Inc., New York, N.Y., 1998. Other protozoans that are inhibited by compounds of formula I include *Plasmodium spp.*, *Leishmania spp.*, *Trypanosoma spp.*, *Cryptosporidium spp.*, *Isospora spp.*, *Cyclospora spp.*, *Trichomonas spp.*, *Microsporidiosis spp.* and the like.

15 The dose of the compound represented by structure I administered varies depending on such factors as the nature and severity of the infection, the age and general health of the recipient and the tolerance of the recipient to the active ingredient. The particular dose regimen likewise can vary according to such factors and can be given in a single daily dose or in multiple doses during the day. The regimen can last from about 2 - 3 days to about 2 - 3 weeks or longer. A typical daily dose (administered in single or divided doses) contains a dosage level of from about 0.01 mg/kg to about 100 mg/kg of body weight of the active compound. Preferred 20 daily doses are generally from about 0.1 mg/kg to about 60 mg/kg, more preferably from about 2.5 mg/kg to about 40 mg/kg.

25 Compound I can be administered parenterally, for example using intramuscular, sub-cutaneous, or intra-peritoneal injection, nasal, or oral means. In addition to these methods of administration, compound I can be applied topically for skin infections.

30 The invention also provides pharmaceutical formulations useful for administering the compounds of the invention. The active ingredient in such formulations comprises from 0.1% to 99.9% by weight of the formulation, more generally from about 10% to about 30% by weight.

For parenteral administration, the formulation comprises Compound I and a physiologically acceptable diluent such as deionized water, physiological saline, 5% dextrose and other commonly used diluents. The formulation can contain a solubilizing agent such as a polyethylene glycol or polypropylene glycol or other known solubilizing agent. Such formulations can be made up in sterile vials containing the active ingredient and one or more excipients in a dry powder or lyophilized powder form. Prior to use, a physiologically acceptable diluent is added and the solution withdrawn via syringe for administration to the recipient.

The pharmaceutical formulations are prepared by known procedures using known and readily available ingredients. In making the compositions of the present invention, the active ingredient will generally be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it can be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active ingredient, soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders and the like.

For oral administration, the active ingredient is filled into gelatin capsules or formed into tablets. Tablets can also contain a binding agent, a dispersant or other excipients suitable for preparing a proper size tablet for the dosage and particular compound of the formula I. For pediatric or geriatric use the active ingredient can be formulated into a flavored liquid suspension, solution or emulsion. A preferred oral formulation is linoleic acid, cremophor RH-60 and water and preferably in the amount (by volume) of 8% linoleic acid, 5% cremophor RH-60, 87% sterile water and a compound of formula I in an amount of from about 2.5 to about 40 mg/mL.

For topical use the active ingredient can be formulated with a dry powder for application to the skin formulated in a liquid formulation comprising a solubilizing aqueous liquid or non-aqueous liquid, e.g., an alcohol or glycol.

09382827.9 - 12205016

Formulations

The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way. The term "active ingredient" refers to a compound represented by structure I or a pharmaceutically acceptable salt thereof.

5

Formulation Example 1

Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
	250
10	200
	10
	460 mg

Formulation Example 2

A tablet is prepared using the ingredients below:

	Quantity (mg/capsule)
	250
15	400
	10
20	5
	665 mg

The components are blended and compressed to form tablets of 665 mg each.

Formulation Example 3

An aerosol solution is prepared containing the following components:

	Weight
	0.25
25	25.75
	74.00
	100.00

30

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation Example 4

35

Tablets, each containing 60 mg of active ingredient, are made as follows:

	Active ingredient	60 mg
	Starch	45 mg
	Microcrystalline cellulose	35 mg
5	Polyvinylpyrrolidone (as 10% solution in water)	4 mg
	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
	Talc	<u>1 mg</u>
	Total	150 mg

The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation Example 5

Capsules, each containing 80 mg of active ingredient, are made as follows:

	Active ingredient	80 mg
20	Starch	59 mg
	Microcrystalline cellulose	59 mg
	Magnesium stearate	<u>2 mg</u>
	Total	200 mg

The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation Example 6

Suppositories, each containing 225 mg of active ingredient, are made as follows:

30	Active ingredient	225 mg
	Saturated fatty acid glycerides	<u>2,000 mg</u>
	Total	2,225 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum

heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Formulation Example 7

Suspensions, each containing 50 mg of active ingredient per 5 mL dose, are made as follows:

Active ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mL
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to total	5 mL

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation Example 8

An intravenous formulation can be prepared as follows:

Active ingredient	100 mg
Isotonic saline	1,000 mL


The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 mL per minute.

05060279 · 020602

CLAIMS

WE CLAIM:

1. A compound represented by structure I:



wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or a heteroaryl group;

R^1 is independently -H, -OH or -O-Pg;

R^2 is -H, -CH₃, -NH₂, or -NH-Ph.

R³ is -H, -CH₃, -CH₂CONH₂, -CH₂CONH-Pg, -CH₂CH₂NH₂, or -CH₂CH₂NH-Pg;

R⁴ is -H, -OH, or -O-Pg;

R^5 is $-\text{OH}$, $-\text{OSO}_3\text{H}$, or $-\text{OPO}_2\text{HR}^a$, where R^a is hydroxy, C₁-C₆ alkyl.


C1-C6 alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzylxylo, *p*-halobenzyl, *p*-halobenzylxylo, *p*-nitrobenzyl, or *p*-nitrobenzylxylo;

R⁶ is -H, -OH, or -OSO₂H.


R^7 is $-H$ or $-CH_3$.

20 *Journal of Safety* • 2015

$\mathbf{P}^{\mathbf{S}}$ is a random variable.



where R^9 is independently -H, -OH, -N₃, -O-Pg, -NH₂, -NH-Pg, or a second sugar moiety comprising one to three sugar units selected from the group consisting of



5 thereof, wherein

R^{9a} is -H, -OH, -N₃, -NH₂, -O-Pg, or -NH-Pg,

R^{9b} is -OPO₂R⁸, -OSO₃H, -H, -NH₂, -OH, -O-Pg, or -NH-Pg,

R^{9c} is -CH₃, -CH₂OH, -CH₂N₃, -CH₂OSO₃H, -CH₂NH-Pg,

-CH₂O-Pg, -CO₂H, or -CO₂-Pg,

10 where R^a is as defined above,


and so long as no more than one R^9 is represented by said second sugar moiety;

Pg is a protecting group; and

pharmaceutically acceptable salts, esters, hydrates or solvates thereof.

15


2. The compound of Claim 1 wherein R is



where A, B, C and D are independently hydrogen, C₁-C₁₂ alkyl, C₂-C₁₂ alkynyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkylthio, halo, or -O-(CH₂)_m-[O-(CH₂)_n]_p-O-(C₁-C₁₂ alkyl) or -O-(CH₂)_q-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and E is hydrogen, C₁-C₁₂ alkyl, C₃-C₁₂ cycloalkyl, benzyl or C₃-C₁₂ cycloalkylmethyl.

5 3. The compound of Claim 2 wherein

10 R¹ is hydroxy at each occurrence;
 R⁴ is hydroxy;
 R⁵ is -OPO₂HR^a, where R^a is methyl or methoxy;
 R², R³, and R⁷ are each methyl; and
 R is a moiety of the formula



15 ; or
 a pharmaceutically acceptable salt or solvate thereof.


20 4. The compound of Claim 3 wherein

R⁵ is hydroxy;
 R is a moiety of the formula




where C is hydrogen or C₃-C₇ alkoxy;

R⁸ is a moiety of the formula



where R⁹ is independently hydrogen, hydroxy, amino, or a moiety of the formula



R^{9b} is -OPO₂R^a, -OSO₃H, -H, -NH₂, -OH, -O-Pg, or -NH-Pg and n is 1, 2, or 3; or


a pharmaceutically acceptable salt or solvate thereof.

5. The compound of Claim 4 wherein
C is n-pentoxy;
R⁹ is independently hydroxy or amino; or a pharmaceutically acceptable salt or solvate thereof.

10 6. The compound of claim 5 wherein
R⁹ is hydroxy at each occurrence; and
t is 2; or a pharmaceutically acceptable salt or solvate thereof.

15 7. A pharmaceutical formulation comprising one or more pharmaceutical carriers, diluents, or excipients and
a compound of Claim 1.

20 8. A method of inhibiting fungal activity comprising administering to a recipient in need of such inhibition an effective amount of a compound represented by structure I:



wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or a heteroaryl group;

R^1 is independently -H, -OH or -O-Rg;

R^2 is $-H$, $-CH_3$, $-NH_2$, or $-NH-PG$.

R^3 is -H, -CH₃, -CH₂CONH₂, -CH₂CONH-Pg, -CH₂CH₂NH₂, or -CH₂CH₂NH-Pg;

R⁴ is -H, -OH or -O-Pg.


R⁵ is -OH, -OSO₃H, or -OPO₂HR^a, where R^a is hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzyloxy, *p*-halobenzyl, *p*-halobenzylxy, *p*-nitrobenzyl, or *p*-nitrobenzylxy;

R^6 is -H, -OH, or -OSO₂H:

R^7 is $-H$ or $-CH_3$.


t is an integer from 2-7:

R^8 is a sugar moiety of the formula



where R⁹ is independently -H, -OH, -N₃, -O-Pg, -NH₂,

-NH-Pg, or a second sugar moiety comprising one to three sugar units selected from the group consisting of



thereof wherein

R^{9a} is -H, -OH, -N₂, -NH₂, -O-Pg, or -NH-Pg

R^{9b} is -OPO₃R^a -OSO₃H -H -NH₂ -OH -O-Pg or -NH-Pg

R^{9c} is -CH₃, -CH₂OH, -CH₂N₃, -CH₂OSO₃H, -CH₂NH-Pg, -CH₂O-Pg, -CO₂H, or -CO₂-Pg.


where R^a is as defined above

and so long as no more than one R^9 is represented by said second sugar moiety:

Pg is a protecting group; and

pharmaceutically acceptable salts, esters, hydrates or solvates thereof

9. The Method of Claim 8 wherein R is



where A, B, C and D are independently hydrogen, C₁-C₁₂ alkyl, C₂-C₁₂ alkynyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkylthio, halo, or -O-(CH₂)_n-[O-(CH₂)_p-O-(C₁-C₁₂ alkyl) or -O-(CH₂)_q-X-E; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4;

5 X is pyrrolidino, piperidino or piperazino; and E is hydrogen, C₁-C₁₂ alkyl, C₃-C₁₂ cycloalkyl, benzyl or C₃-C₁₂ cycloalkylmethyl.

10. The method of claim 8 wherein the recipient is a human.

11. The method of Claim 9 wherein


R¹ is hydroxy at each occurrence;

R⁴ is hydroxy;

R⁵ is -OPO₂HR⁸, where R⁸ is methyl or methoxy;

R², R³, and R⁷ are each methyl; and

15 R is a moiety of the formula




a pharmaceutically acceptable salt or solvate thereof.

12. The method of Claim 9 wherein


20 R⁵ is hydroxy;

R is a moiety of the formula




where C is hydrogen or C₃-C₇ alkoxy;

R⁸ is a moiety of the formula



25

where R^9 is independently hydrogen, hydroxy, amino, or a moiety of the formula



5 R^{9b} is $-OPO_2R^a$, $-OSO_3H$, $-H$, $-NH_2$, $-OH$, $-O-Pg$, or
 $-NH-Pg$ and n is 1, 2, or 3; or
a pharmaceutically acceptable salt or solvate thereof.


10 13. The method of Claim 12 wherein
 C is n-pentoxy;
 R^9 is independently hydroxy or amino; or a pharmaceutically acceptable salt or solvate thereof.

15 14. The method of claim 13 wherein
 R^9 is hydroxy at each occurrence; and
 t is 2; or a pharmaceutically acceptable salt or solvate thereof.

20 15. The method according to Claim 8 wherein the fungal activity arises from one or more of the fungi selected from the group consisting of *Candida albicans*, *Aspergillus fumigatus*, and *Candida parapsilosis*.

16. A method of inhibiting parasitic activity comprising administering to a recipient in need of such inhibition an effective amount of a compound represented by structure I:

00000000000000000000000000000000



wherein

R is an alkyl group, an alkenyl group, an alkynyl group, an aryl group, or a heteroaryl group.

R¹ is independently -H, -OH or -O-Pg;

R^2 is -H, -CH₃, -NH₂, or -NH-Pg:

R³ is -H, -CH₃, -CH₂CONH₂, -CH₂CONH-Pg, -CH₂CH₂NH₂, or -CH₂CH₂NH-Pg.

R⁴ is -H, -OH, or -O-Pg.


R^5 is $-OH$, $-OSO_3H$, or $-OPO_2HR^a$, where R^5 is hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, phenyl, phenoxy, *p*-halophenyl, *p*-halophenoxy, *p*-nitrophenyl, *p*-nitrophenoxy, benzyl, benzyloxy, *p*-halobenzyl, *p*-halobenzyloxy, *p*-nitrobenzyl, or *p*-nitrobenzyloxy;

R^6 is $-H$, $-OH$, or $-OSO_3H$:

R^7 is $-H$ or $-CH_3$:


t is an integer from 2-7;

R^8 is a sugar moiety of the formula



where R⁹ is independently -H, -OH, -N₃, -O-Pg, -NH₂,


-NH-Pg, or a second sugar moiety comprising one to three sugar units selected from the group consisting of



thereof, wherein

5 R^{9a} is -H, -OH, -N₃, -NH₂, -O-Pg, or -NH-Pg,
 R^{9b} is -OPO₂R⁸, -OSO₃H, -H, -NH₂, -OH, -O-Pg, or -NH-Pg,
 R^{9c} is -CH₃, -CH₂OH, -CH₂N₃, -CH₂OSO₃H, -CH₂NH-Pg,
-CH₂O-Pg, -CO₂H, or -CO₂Pg,
where R^8 is as defined above,
10 and so long as no more than one R^9 is represented by said second sugar moiety,
Pg is a protecting group; and
pharmaceutically acceptable salts, esters, hydrates or solvates thereof.

17. The Method of Claim 16 wherein R is



where A, B, C and D are independently hydrogen, C₁-C₁₂ alkyl, C₂-C₁₂ alkynyl,

C₁-C₁₂ alkoxy, C₁-C₁₂ alkylthio, halo, or

-O-(CH₂)_m-[O-(CH₂)_n]_p-O-(C₁-C₁₂ alkyl) or -O-(CH₂)_q-X-E;

m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4;

5 X is pyrrolidino, piperidino or piperazino; and E is hydrogen, C₁-C₁₂ alkyl, C₃-C₁₂ cycloalkyl, benzyl or C₃-C₁₂ cycloalkylmethyl.

18. The method of claim 16 wherein the recipient is a human.

10 19. The method of Claim 17 wherein


R¹ is hydroxy at each occurrence;

R⁴ is hydroxy;

R⁵ is -OPO₂HR⁴, where R⁸ is methyl or methoxy;

R², R³, and R⁷ are each methyl; and

15 R is a moiety of the formula




18. A pharmaceutically acceptable salt or solvate thereof.

20. The method of Claim 17 wherein


R⁵ is hydroxy;

R is a moiety of the formula




where C is hydrogen or C₃-C₇ alkoxy;

R⁸ is a moiety of the formula



25

where R^9 is independently hydrogen, hydroxy, amino, or a moiety of the formula



R^{9b} is $-OPO_2R^a$, $-OSO_3H$, $-H$, $-NH_2$, $-OH$, $-O-Pg$, or

5 $-NH-Pg$ and n is 1, 2, or 3; or

a pharmaceutically acceptable salt or solvate thereof.

21. The method of Claim 20 wherein

C is n -pentoxyl;

10 R^9 is independently hydroxy or amino; or a pharmaceutically acceptable salt or solvate thereof.

22. The method of claim 21 wherein

R^9 is hydroxy at each occurrence; and

15 t is 2; or a pharmaceutically acceptable salt or solvate thereof.

23. The method of Claim 16 wherein the parasitic activity arises from
Pneumocystis carinii.

09868279 020600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Michael J. RODRIGUEZ, et al.

Serial No.: 09/868,347

371 Filing Date: June 15, 2001

For: CYCLIC PEPTIDE ANTIFUNGAL
AGENTS

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

**PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY
UNDER 37 C.F.R. § 3.71**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Eli Lilly and Company, the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

77

Lisa A. Amii (Reg No. 48,199)
Mehran Arjomand (Reg No. P48,231)
Sanjay S. Bagade (Reg No. 42,280)
Shantanu Basu (Reg No. 43,318)
Vincent J. Belusko (Reg No. 30,820)
Kimberly A. Bolin (Reg No. 44,546)
Tyler S. Brown (Reg No. 36,465)
A. Randall Camacho (Reg No. 46,595)
Robert K. Cerpa (Reg No. 39,933)
Alex Chartova (Reg No. 31,942)
Thomas E. Ciotti (Reg No. 21,013)
Matthew M. D'Amore (Reg No. 42,457)
Peter Davis (Reg No. 36,119)
Stephen C. Durant (Reg No. 31,506)
David L. Fehrman (Reg No. 28,600)
Thomas George (Reg No. 45,740)
Kenneth R. Glick (Reg No. 28,612)

Randolph Ted Apple (Reg No. 36,429)
Laurie A. Axford (Reg No. 35,053)
Erwin J. Basinski (Reg No. 34,773)
Richard R. Batt (Reg No. 43,485)
Jonathan Bockman (Reg No. 45,640)
Barry E. Bretschneider (Reg No. 28,055)
Nicholas Buffinger (Reg No. 39,124)
Mark R. Carter (Reg No. 39,131)
Peng Chen (Reg No. 43,543)
Thomas Chuang (Reg No. 44,616)
Cara M. Coburn (Reg No. 46,631)
Raj S. Davé (Reg No. 42,465)
Karen B. Dow (Reg No. 29,684)
Carolyn A. Favorito (Reg No. 39,183)
Hector Gallegos (Reg No. 40,614)
Debra J. Glaister (Reg No. 33,888)
Bruce D. Grant (Reg No. 47,608)

209020-10276-088360

Johney U. Han (Reg No. 45,565)
Alan S. Hodes (Reg No. 38,185)
Kelvan P. Howard (Reg No. P48,999)
Jill A. Jacobson (Reg No. 40,030)
Madeline I. Johnston (Reg No. 36,174)
Ararat Kapouyan (Reg No. 40,044)
Cameron A. King (Reg No. 41,897)
Kawai Lau (Reg No. 44,461)
Rimas T. Lukas (Reg No. 46,451)
Gladys H. Monroe (Reg No. 32,430)
Kate H. Murashige (Reg No. 29,959)
Mabel Ng (Reg No. P48,922)
Catherine M. Polizzi (Reg No. 40,130)
Debra A. Shetka (Reg No. 33,309)
Rebecca Shortle (Reg No. 47,083)
Stanley H. Thompson (Reg No. 45,160)
Brenda J. Wallach (Reg No. 45,193)
E. Thomas Wheelock (Reg No. 28,825)
Frank Wu (Reg No. 41,386)
Peter J. Yim (Reg No. 44,417)
Karen R. Zachow (Reg No. 46,332)

Douglas G. Hodder (Reg No. 41,840)
Charles D. Holland (Reg No. 35,196)
Peter Hsieh (Reg No. 44,780)
Wayne Jaeschke, Jr. (Reg No. 38,503)
Parisa Jorjani (Reg No. 46,813)
Richard C. Kim (Reg No. 40,046)
Lawrence B. Kong (Reg No. P49,043)
Glen Kubota (Reg No. 44,197)
Michael J. Mauriel (Reg No. 44,226)
Philip A. Morin (Reg No. P45,926)
Paul S. Naik (Reg No. P49,075)
Martin M. Noonan (Reg No. 44,264)
Phillip Reilly (Reg No. 41,415)
Terri Shieh-Newton (Reg No. 47,081)
Kevin R. Spivak (Reg No. 43,148)
Thomas L. Treffert (Reg No. P48,279)
Michael R. Ward (Reg No. 38,651)
Todd W. Wight (Reg No. 45,218)
David T. Yang (Reg No. 44,415)
George C. Yu (Reg No. 44,418)
Arlene Palmberg (Reg No. 40,422)
Charles E. Cohen (Reg No. 34,565)

of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, or of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

Please direct all written communications relative to this application to:

Madeline I. Johnston
Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018

Please direct all telephone communications to Madeline I. Johnston at (650) 813-5840.

Eli Lilly and Company
an Indiana corporation

Dated:

1/27/02 Douglas K. Norman

Name: Douglas K. Norman
Title: Deputy General Patent Counsel
Address: Lilly Corporate Center
Indianapolis, Indiana 46285

09868279.020602

DECLARATION FOR PATENT APPLICATION (Includes Reference to PCT International Applications)	ATTORNEY'S DOCKET NUMBER 342312003500
---	--

As a below named inventor I hereby declare that:

Our residences, post office addresses and citizenship are as stated below next to our names,

We believe we the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CYCLOC PEPTIDE ANTIFUNGAL AGENTS HAVING A SUGAR SUBSTITUENT

the specification of which (check only one item below):

- is attached hereto.
- was filed as United States application

Serial No.
on
and was amended on (if applicable).

- was filed as PCT international application



Number PCT/US99/29927
on December 15, 1999
and was amended under PCT Article 19
on (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37 Code of Federal Regulations § 1.56(a) and (b).

We hereby claim foreign priority benefits under Title 35 United States Code § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119:			
COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
United States	60/112,433	December 16, 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

Declaration for Patent Application (Continued) (Includes Reference to PCT International Applications)			ATTORNEY'S DOCKET NUMBER 342312003500		
<p>We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:					
U.S. APPLICATIONS			STATUS (Check one)		
U.S APPLICATION NUMBER		U.S. FILING DATE	PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.			STATUS (Check one)		
PCT APPLICATION NUMBER		PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)	PATENTED	PENDING
Send correspondence to:				Direct telephone calls to:	
     Madeline I. Johnston Morrison & Foerster LLP 755 Page Mill Road Palo Alto, California 94304-1018				Madeline I. Johnston at (650) 813-5840	
201.1	FULL NAME OF INVENTOR	FAMILY NAME <u>RODRIGUEZ</u>	FIRST GIVEN NAME <u>Michael</u>	SECOND GIVEN NAME <u>John</u>	
	RESIDENCE & CITIZENSHIP	CITY <u>Indianapolis</u>	STATE OR FOREIGN COUNTRY <u>Indiana</u>	COUNTRY OF CITIZENSHIP <u>United States of America</u>	
	POST OFFICE ADDRESS	1825 Sailing Court	CITY <u>Indianapolis</u>	STATE & ZIP CODE/COUNTRY <u>Indiana 46260</u>	
202.1	FULL NAME OF INVENTOR	FAMILY NAME <u>NESLER</u>	FIRST GIVEN NAME <u>Michael</u>	SECOND GIVEN NAME <u>John</u>	
	RESIDENCE & CITIZENSHIP	CITY <u>Bozrah</u>	STATE OR FOREIGN COUNTRY <u>Connecticut</u>	COUNTRY OF CITIZENSHIP <u>United States of America</u>	
	POST OFFICE ADDRESS	195 Lake Road	CITY <u>Bozrah</u>	STATE & ZIP CODE/COUNTRY <u>Connecticut 06334</u>	
203.1	FULL NAME OF INVENTOR	FAMILY NAME <u>ZWEIFEL</u>	FIRST GIVEN NAME <u>Mark</u>	SECOND GIVEN NAME <u>James</u>	
	RESIDENCE & CITIZENSHIP	CITY <u>Indianapolis</u>	STATE OR FOREIGN COUNTRY <u>Indiana</u>	COUNTRY OF CITIZENSHIP <u>United States of America</u>	
	POST OFFICE ADDRESS	7519 Higdon Court	CITY <u>Indianapolis</u>	STATE & ZIP CODE/COUNTRY <u>Indiana 46214</u>	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.</p>					
SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203			
					
DATE 1/22/02	DATE 1-14-02	DATE 1/22/2002			